Sunday, August 20, 2017 2:57:04 PM
Only problem, this is "ALL TALK" / "NO ACTION". This is the same old story heavily promoted for several years "here is what we are doing" but "we have never delivered on it for several years". We never executed on any presentation and never delivered and reported any real progress, data and/or material committments to date, always late on everything, full of mistakes, but believe TPIV now, TPIV has another great presentation on the website. In the absence od data need credibility, there is no credibility here. Let's recap recent history:
1. TRIBLive interview Wilson stated "TapImmune may have to do further Phase 2 studies before the pivotal Phase 3 studies that would allow licensure of the vaccine(s) over the next several years". This is first time I ever heard this, looks like Wilson is telegraphing more Phase 2 trials with a subtle comment so he does not get in trouble (kind of slimy). There goes the $10 Million cash but is it $10 Million, TPIV has millions in Accounts Payable at present, just how much available cash does TPIV have?
2. Where is the MAYO Paper for Phase 1 Long Term Results, you know the study that had 10 patients and is not statistically significant? Are the immune responses really durable versus competition? Are the other MAYO/DOD sponsored trials at risk until the paper is published and vetted within the Industry - YES. Is the DOD dealing with potential budget cuts - YES. Does the MAYO Phase 1 paper need to be compelling to maintain DOD funds and MAYO trials - YES. Is MAYO going to publish a paper or not, and where is it and when? Wilson stated "soon" several weeks ago, it appears he is late again.
3. AZN now has a combination maintenance therapy for ovarial cancer with Merck and it does not involve Durvamulab/TPIV 200. AZN has recent trial disappointments with Durvalumab which create much greater uncertainty for the TPIV combination trial with AZN/MSK.
4. Continued turnover at TapImmune delaying schedule and costing more money. Wilson can not maintain a staff, however, can hire someone to make a hell of a presentation.
5. Another round of disappointing financing creating significant dilution and all but capping near to intermediate term share price gains at current price or lower.
6. TPIV200 FDA trial amendment to make trial statistically significant and increase coverage, both sould have been addressed prior to initiating trials. Continuing mistakes made by Wilson and TPIV, they are like a hamster on a hamster wheel, running but never getting anywhere.
7. No action by TPIV BOD to respond to poor performance of TPIV management like Wilson. There is a questionable relationship and business between TPIV Management, some TPIV BOD and former employees at Iroquios and related companies. A similar relationship and potential legal action outcome was outlined in a Seeking Alpha article on the stock Neurotrope (NTRP). The article mentioned TPIV. Also, there has been "talk" of investors manipulating stock price, pushing TPIV share price lower resulting in significant reduction in strike price for current investor warrants. This was communicated to Wilson several times by a shareholder. Did large investors dump shares to suppress share price and then have strike prices for warrants reduced? Why aren't large investors upset at present? As a result, why isn't Wilson terminated, maybe it is because initial investors sold shares to cover their initial investment while realizing a lower strike price for warrants, thereby lowering overall acquisition cost and related risk.
In summary, great presentation, a hallmark of TPIV, we need real progress and date. In the absence of real data and progress you need to have someone at TapImmune that is credible, I am not sure if we have too many people at Tapimmune who are credible at present and some due to questionable behavior need to leave now. Do not let these guys pump you up too much, buy TPIV at an atractive price lower than where it is now not higher until we have something real and we get credible manafement. GLTA
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM